New combo therapy targets Hard-to-Treat lymphoma
NCT ID NCT06054776
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combination of three drugs—acalabrutinib, obinutuzumab, and glofitamab—can safely treat mantle cell lymphoma that has come back or not responded to prior therapy. The drugs work by blocking cancer growth signals and helping the immune system attack cancer cells. About 40 adults with this type of lymphoma will participate. The main goals are to check side effects and see how many patients achieve a complete response (no cancer detected).
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Can a targeted drug boost standard chemo for a rare blood cancer?
- Smartwatches track hidden heart risk in blood cancer patients